Amended Current Report Filing (8-k/a)
April 21 2020 - 4:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 30, 2020
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37348
|
|
46-4348039
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
500
River Ridge Drive, Norwood, MA
|
|
02062
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (617) 963-0100
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
CRBP
|
|
The
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act
of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Explanatory
Note
This
Amendment No. 1 amends the Current Report on Form 8-K of Corbus Pharmaceuticals Holdings, Inc. (the “Company”) filed
on April 1, 2020 (the “Original 8-K”) to provide updated information reported under Item 5.02. Except as set forth
herein, no other modifications have been made to the Original Form 8-K.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
As
previously disclosed, on March 30, 2020, the Compensation Committee of the Company approved the terms of amended and restated
employment agreements (the “Employment Agreements”) with certain of the Company’s executive officers: Yuval
Cohen, Ph.D., Chief Executive Officer; Barbara White, M.D., Chief Medical Officer; and Sean Moran, Chief Financial Officer (the
“Executives”), copies of which are incorporated by reference herein. On April 17, 2020 and April 21, 2020,
the Executives entered into certain amended and restated employment agreements with the Company (the “Revised Employment
Agreements”) that contained certain updates, which were approved by the Compensation Committee, to the forms
of Employment Agreements previously filed with the Original 8-K. The updates to the Employment Agreements include revising the
length of the post-termination non-compete period from twelve months to six months from the date of cessation of the Executive’s
employment with the Company and other immaterial changes to the Employment Agreements.
Item
9.01. Financial Statements and Exhibits.
(d)
The following exhibits are furnished with this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
|
|
|
|
Date:
April 21, 2020
|
By:
|
/s/
Yuval Cohen
|
|
Name:
|
Yuval
Cohen
|
|
Title:
|
Chief
Executive Officer
|
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From May 2024 to Jun 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jun 2023 to Jun 2024